Funded through a CHF2.5 million endowment, the objective of the chair is to leverage the wide scope of ideas and inventions discovered by EPFL scientists and the global drug development expertise of Debiopharm. The synergy expected through this partnership will maximise the chances of bringing innovative drugs to patients.
Under the terms of the agreement, Debiopharm will also finance other potential collaborative research projects of mutual interest to both parties and will have the option to endow a second chair in drug design.